Ligand validation:2GL9

ASN: ASPARAGINE

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
2GL9_ASN_D_597	44%	47%	0.183	0.91	1.02	1.01	-	-	2	0	100%	0.722
2GL9_ASN_B_297	42%	61%	0.168	0.885	0.77	0.74	-	-	0	0	100%	0.8
6PA3_ASN_C_401	99%	43%	0.047	0.976	1.32	0.92	1	-	0	0	100%	1
6PA5_ASN_H_401	98%	53%	0.056	0.979	0.79	1.02	-	1	0	0	100%	1
6PA6_ASN_D_401	98%	49%	0.045	0.964	0.93	1.04	1	1	0	0	100%	1
6FXG_ASN_C_301	97%	68%	0.057	0.972	0.76	0.5	-	-	0	0	100%	1
6PA8_ASN_C_401	97%	44%	0.066	0.981	0.99	1.16	1	1	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.